Opus Genetics Inc
Company Profile
Business description
Opus Genetics Inc is a clinical-stage ophthalmic biopharmaceutical company developing therapies to treat patients with inherited retinal diseases (IRDs) and therapies to treat patients with other retinal and refractive disorders. The pipeline includes adeno-associated virus (AAV)-based gene therapies that address mutations in genes that cause different forms of bestrophinopathy, Leber congenital amaurosis (LCA) and retinitis pigmentosa. The pipeline also includes Phentolamine Ophthalmic Solution 0.75%, a non-selective alpha-1 and alpha-2 adrenergic antagonist to reduce pupil size, and APX3330, a novel small-molecule inhibitor of Ref-1 to slow the progression of non-proliferative diabetic retinopathy.
Contact
37000 Grand River Avenue
Suite 120
Farmington HillsMI48335
USAT: +1 248 957-9024
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
14
Stocks News & Analysis
stocks
The lessons behind the best performing stock over the last 80 years
stocks
10 of the cheapest global companies with wide moats
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,089.90 | 7.80 | 0.10% |
| CAC 40 | 8,114.57 | 40.59 | 0.50% |
| DAX 40 | 23,393.23 | 238.66 | 1.03% |
| Dow JONES (US) | 41,472.25 | 369.38 | -0.88% |
| FTSE 100 | 8,705.23 | 24.94 | 0.29% |
| HKSE | 24,740.57 | 595.00 | 2.46% |
| NASDAQ | 17,498.52 | 310.15 | -1.74% |
| Nikkei 225 | 37,845.42 | 448.90 | 1.20% |
| NZX 50 Index | 12,076.85 | 89.29 | -0.73% |
| S&P 500 | 5,607.63 | 67.49 | -1.19% |
| S&P/ASX 200 | 7,860.40 | 6.30 | 0.08% |
| SSE Composite Index | 3,429.76 | 3.63 | 0.11% |